November 10, 2024
To | To |
Listing Department, | The Corporate Relations Department |
NATIONAL STOCK EXCHANGE OF INDIA LIMITED | BSE LIMITED |
Exchange Plaza, | Phiroz Jeejeebhoy Towers, |
Bandra Kurla Complex, Bandra (E), | 25th floor, Dalal Street, |
MUMBAI -400 051 | MUMBAI -400 001 |
Company Code No. AUROPHARMA | Company Code No. 524804 |
Dear Sir / Madam,
Sub: Corrigendum to the Statement of Unaudited Consolidated financial results of the Company for the quarter and half year ended 30 September 2024 - Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations")
Ref: Our letter dated November 9, 2024 intimating the Outcome of Board Meeting.
This is to inform that the Board of Directors of the Company had in its meeting held on November 9, 2024, approved the Statement of Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended on September 30, 2024 and the necessary disclosures were made under Regulation 30 of the SEBI Listing Regulations vide acknowledgement nos. NSE 2024/Nov/6907/6984 and BSE 8190588 dated November 9, 2024.
Subsequently, a typographical error was noticed in the Statement of Unaudited Consolidated Financial Results in point no. 12 under the heading of 'Out of total comprehensive income above, Profit for the year attributable to Owners of the Holding Company' for the unaudited half year ended September 30, 2023, which was erroneously mentioned as 9,299.9 instead of 13,279.3.
We confirm that there is no other change in the Statement of Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2024 and also confirm that the rectification of the aforesaid error does not have any impact on the consolidated financial results for the quarter and half year ended September 30, 2024, as reviewed by the Audit Committee and Approved by the Board of Directors of the Company or any other information disclosed. We regret the inconvenience caused, if any.
We now submit Statement of Unaudited Consolidated Financial Results for the quarter and half-year ended on September 30, 2024 correcting the aforesaid typographical error.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by BADDIGAM
ADI REDDY
Date: 2024.11.10 13:48:00 +05'30'
B. Adi Reddy
Company Secretary
Enclosures: as above
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com